PeptidePedia The community reference

Special:RecentChanges

Change log·6,798 revisions·page 49 of 68

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 6,798 changes are logged in total.

6,798Logged changes
575Bot edits
167Page creations
256Active editors

3 February 2025

  1. (diff | hist) 01:40 Sarcopenia 2,738 ±0 OrphanPageOrin (talk | contribs) add the units and the conversion factor to SI [rollback]

2 February 2025

  1. (diff | hist) 18:34 Reverse-phase HPLC 4,246 ±0 DiluentDiya (talk | contribs) expand §Conditions and what they control [rollback]
  2. (diff | hist) m 15:24 ChinaPeptides 6,528 +375 GroupBuyGalen (talk | contribs) serial comma per PP:MOS [rollback]
  3. (diff | hist) m 14:42 Adverse effects of GLP-1 receptor agonists 4,482 ±0 DrTitration (talk | contribs) correct the percentage — source reports it per patient-year [rollback]
  4. (diff | hist) 13:19 Talk:Shanghai Wibson Biotechnology 611 +351 ScopeSeverin (talk | contribs) /* Notability: what a five-year registry history establishes */ reply
  5. (diff | hist) 12:07 Growth hormone secretagogue 3,350 +629 UnderfillUna (talk | contribs) alphabetise the see-also list [rollback]
  6. (diff | hist) 11:45 Residual solvent 3,736 +129 IsocraticIla (talk | contribs) space between number and unit per PP:MOS [rollback]
  7. (diff | hist) 10:36 Talk:Shanghai Wibson Biotechnology 400 +410 NotabilityNoa (talk | contribs) /* Notability: what a five-year registry history establishes */ new section
  8. (diff | hist) 10:31 SUSTAIN trial programme 4,169 ±0 TrialsTabitha (talk | contribs) expand §SUSTAIN 6 and its interpretation [rollback]
  9. (diff | hist) m 06:51 Deamidation 3,531 +34 RedirectRini (talk | contribs) add the figure for the chromatogram and caption its axes [rollback]
  10. (diff | hist) m b 06:31 Haemoglobin A1c 3,366 +148 CiteBot (talk | contribs) bot: add stub category [rollback]
  11. (diff | hist) 03:43 Active pharmaceutical ingredient 2,832 ±0 API_Aurora (talk | contribs) add the good-manufacturing-practice framework by name [rollback]
  12. (diff | hist) 03:07 Contraindications of incretin therapy 3,374 +721 ResinRhoswen (talk | contribs) correct the renal statement — the caution is about volume depletion [rollback]

1 February 2025

  1. (diff | hist) 23:03 Loss on drying 3,338 ±0 HOMA_Hettie (talk | contribs) expand §Why the distinction from water matters [rollback]
  2. (diff | hist) 18:30 Body composition assessment 3,353 ±0 eGFR_Esme (talk | contribs) add the standardisation programme the assay is traceable to [rollback]
  3. (diff | hist) 18:12 Arcuate nucleus 3,874 +101 ProglucagonPia (talk | contribs) rm the causal claim about appetite — the cited work is associative [rollback]
  4. (diff | hist) 16:57 Reference standard 4,120 +353 TechnicianTeal (talk | contribs) add category for method validation [rollback]
  5. (diff | hist) m 13:06 Insulin syringe 4,111 +334 MicrodoseMagnus (talk | contribs) fix the arithmetic in the worked reconstitution example [rollback]
  6. (diff | hist) 06:29 Fasting insulin 2,962 +672 CRP_Cormac (talk | contribs) ce per PP:MOS [rollback]
  7. (diff | hist) 06:21 Satiety signalling 4,441 +363 CitationChaser (talk | contribs) the article treated a rodent finding as human physiology; corrected [rollback]

31 January 2025

  1. (diff | hist) 23:22 Multi-dose vial 2,077 ±0 ResinRhoswen (talk | contribs) add the preservative point: unpreserved diluent changes the interval [rollback]
  2. (diff | hist) 17:27 Amylin receptor agonist 3,532 ±0 MissedDoseMik (talk | contribs) fix a broken wikilink [rollback]
  3. (diff | hist) m 13:52 Receptor bias 3,236 +84 LCellLeif (talk | contribs) distinguish the active and total forms of the hormone throughout [rollback]
  4. (diff | hist) 13:50 Beta cell function 4,328 ±0 PriorAuthPaz (talk | contribs) split §Physiology from §Pharmacological exploitation [rollback]
  5. (diff | hist) m 09:13 Shanghai Wibson Biotechnology 2,196 ±0 PurityClaimPia (talk | contribs) clarify that a registered business scope is a licensing fact, not a quality assurance [rollback]
  6. (diff | hist) 02:49 Retention time 3,306 ±0 RepackRadek (talk | contribs) add the ionisation mode to the mass-spectrometry description [rollback]
  7. (diff | hist) m 02:09 Shanghai Sigma-Audley New Material Technology 6,196 ±0 TallySheetTad (talk | contribs) expand §Distribution and dispatch [rollback]

30 January 2025

  1. (diff | hist) 23:03 Oral semaglutide 3,519 +278 StopperingSteff (talk | contribs) attribute the potency comparison to the head-to-head trial rather than to two separate ones [rollback]
  2. (diff | hist) m 14:43 TRIUMPH trial programme 3,495 +99 TriumphThad (talk | contribs) state the non-inferiority margin, since the design was non-inferiority [rollback]
  3. (diff | hist) 14:39 MOTS-c 2,663 ±0 ThymosinTamsin (talk | contribs) expand §Material in research supply [rollback]
  4. (diff | hist) 08:36 Peptide content 4,932 +122 ImportRecordIna (talk | contribs) expand §Why it is so often absent [rollback]
  5. (diff | hist) m 07:54 Prior authorisation 2,250 +246 FmocFrancis (talk | contribs) add the year each price figure refers to [rollback]
  6. (diff | hist) 07:28 Vial 17,132 +1,080 FiveOhThreeB (talk | contribs) the article confused primary and secondary drying; corrected [rollback]
  7. (diff | hist) m b 06:31 Counterfeit peptide 2,733 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]
  8. (diff | hist) 04:38 Regulatory status by jurisdiction 2,721 ±0 ImportPolicyIggy (talk | contribs) name the regulator rather than writing "the authorities" [rollback]
  9. (diff | hist) 02:16 Bachem Holding (Suzhou) 7,235 +611 BUD_Bertram (talk | contribs) add the lead time for catalogue lines, as reported [rollback]

29 January 2025

  1. (diff | hist) 19:44 Exenatide 3,419 ±0 PurityClaimPia (talk | contribs) add the receptor targets to the lead sentence [rollback]
  2. (diff | hist) 19:11 Bacteriostatic water 3,824 +247 BUD_Bertram (talk | contribs) state the number of doses a vial yields at that concentration [rollback]
  3. (diff | hist) 16:51 Batch number 3,708 +218 ToneTilda (talk | contribs) de-orphan [rollback]
  4. (diff | hist) m 15:39 Resin cleavage 3,277 +196 PeakShapePol (talk | contribs) add the crimp-seal step to the fill-and-finish description [rollback]
  5. (diff | hist) 14:49 Trial data comparison 2,220 +171 ScopeSeverin (talk | contribs) add the trial and year to each row of the comparison [rollback]
  6. (diff | hist) 14:29 Intention-to-treat analysis 3,795 ±0 SVG_Solomon (talk | contribs) attribute the subgroup finding as exploratory [rollback]
  7. (diff | hist) 13:20 Placebo-adjusted effect 2,887 +34 ForestPlotFinn (talk | contribs) expand §Where the adjustment is not enough [rollback]
  8. (diff | hist) 12:46 Dual incretin agonist 4,587 ±0 OrforglipronOona (talk | contribs) state plainly that the research-use-only form is not approved for human use [rollback]
  9. (diff | hist) m 12:36 Reconstitution of lyophilised peptides 4,173 ±0 TitrationTheo (talk | contribs) close an unbalanced quotation mark [rollback]
  10. (diff | hist) m 11:05 SELECT trial 4,206 +29 ForestPlotFinn (talk | contribs) rm the survival claim — no mortality endpoint was pre-specified [rollback]
  11. (diff | hist) 08:30 Glucagon 4,913 ±0 CuriousCallum (talk | contribs) expand §Receptor and signalling [rollback]
  12. (diff | hist) m b 07:22 Personal importation policy 2,232 ±0 CategoryBot (talk | contribs) bot: expand DOI to full citation [rollback]
  13. (diff | hist) 05:04 Global access disparity 2,195 +218 AnalyticalAnnie (talk | contribs) split §Pricing from §Coverage [rollback]
  14. (diff | hist) 03:02 Third-party testing 5,087 +26 MelanocortinMil (talk | contribs) add the citation for the blind-sampling discussion [rollback]
  15. (diff | hist) 02:32 Sangon Biotech 4,995 +192 EpitalonEoin (talk | contribs) rm the comparison with another supplier; there is no common basis for it [rollback]

28 January 2025

  1. (diff | hist) 20:38 GLP-1 receptor agonist 9,254 +1,083 MolarMassMaeve (talk | contribs) add the excipient list from the labelling [rollback]
  2. (diff | hist) 17:57 Triple agonist 3,147 +27 GMP_Gita (talk | contribs) convert the substitution list to a table so the analogues line up [rollback]
  3. (diff | hist) m b 09:11 Tianjin Finder Chemical 5,811 +417 CategoryBot (talk | contribs) bot: sort category members [rollback]
  4. (diff | hist) N 09:00 Multi-dose vial 2,077 +2,077 SharpsSukhi (talk | contribs) start article; worked example to follow
  5. (diff | hist) m 07:07 Enteroendocrine L cell 4,619 +512 ColumnOvenCoy (talk | contribs) space between number and unit per PP:MOS [rollback]
  6. (diff | hist) m 05:03 Peptide synthesis 4,113 ±0 CustomsClarke (talk | contribs) ce, tighten prose [rollback]
  7. (diff | hist) 03:36 Janoshik Analytical 4,126 ±0 SurpassSunniva (talk | contribs) state the date range the submitted set covers [rollback]
  8. (diff | hist) 01:03 Prescribing information 3,458 +135 CostPerMgCory (talk | contribs) add the manufacturer assistance programme with its eligibility criterion [rollback]

27 January 2025

  1. (diff | hist) m 21:00 Test report forgery 3,874 +265 CouplingCillian (talk | contribs) state that the report identifies the sample, not the shipment [rollback]
  2. (diff | hist) m b 10:56 Orforglipron 3,337 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]
  3. (diff | hist) 06:11 CagriSema 2,989 +74 UnderfillUna (talk | contribs) add the molecular formula to the infobox [rollback]
  4. (diff | hist) 05:22 Cost per milligram 1,917 +33 TierTwoTansy (talk | contribs) add the prior-authorisation criterion as attributed to the payer document [rollback]
  5. (diff | hist) m b 04:06 SURMOUNT trial programme 3,270 ±0 CiteBot (talk | contribs) bot: sort category members [rollback]
  6. (diff | hist) 02:23 Methionine oxidation 2,680 ±0 Ref_Desk_Ron (talk | contribs) expand §Chemistry and promoters [rollback]

26 January 2025

  1. (diff | hist) 18:44 Bacterial endotoxin test 4,398 +296 BiosimilarBoaz (talk | contribs) add the note on co-elution and what it hides [rollback]
  2. (diff | hist) m 15:22 Purity claim inflation 3,067 ±0 ExenatideEzra (talk | contribs) add the second-opinion point: two services, one lot, is a stronger record [rollback]
  3. (diff | hist) m 12:21 GLP-1 receptor 5,522 ±0 SPPS_Sorrel (talk | contribs) rm the causal claim about appetite — the cited work is associative [rollback]
  4. (diff | hist) 09:18 Sterile water for injection 3,619 +390 RotationRosalind (talk | contribs) fix the arithmetic in the worked reconstitution example [rollback]
  5. (diff | hist) 08:27 List of GLP-1 receptor agonists 3,023 ±0 Retention_Time_Rae (talk | contribs) renumber the timeline after inserting the 2023 entry [rollback]
  6. (diff | hist) 06:49 Melanotan II 2,703 ±0 API_Aurora (talk | contribs) fix a dangling clause [rollback]
  7. (diff | hist) 06:00 Liraglutide 4,295 ±0 EscalationEira (talk | contribs) split overlong sentence [rollback]
  8. (diff | hist) 05:32 Patent expiry and biosimilars 2,578 ±0 ShortageShona (talk | contribs) add the patent-expiry statement, attributed and dated [rollback]
  9. (diff | hist) 04:47 Retatrutide 5,700 +1,103 LiraLotte (talk | contribs) label the animal data as animal data in the sentence, not only in the section heading [rollback]
  10. (diff | hist) 02:43 Reconstitution calculator 4,456 +151 NauseaNoor (talk | contribs) add keyboard operation to the control description [rollback]

25 January 2025

  1. (diff | hist) 23:37 Albumin binding half-life extension 4,511 +110 BUD_Bertram (talk | contribs) expand §Physical basis [rollback]
  2. (diff | hist) 22:23 Beyond-use date 9,787 +900 eGFR_Esme (talk | contribs) add the dead-space volume to the worked example [rollback]
  3. (diff | hist) m 20:37 Aspiration risk under anaesthesia 3,608 +30 SiteReactionSuz (talk | contribs) flag the section as needing a source for two remaining figures [rollback]
  4. (diff | hist) 19:55 USP General Chapter 85 3,416 +748 DrTitration (talk | contribs) add the system-suitability criteria the method actually specifies [rollback]
  5. (diff | hist) 14:14 Grey market 2,576 ±0 FmocFrancis (talk | contribs) expand §Relevance to this wiki [rollback]
  6. (diff | hist) 10:28 STEP trial programme 4,357 +293 ToleranceTove (talk | contribs) correct the baseline mean — transposed digits [rollback]
  7. (diff | hist) 10:14 Talk:Bachem Holding (Suzhou) 1,455 +156 RfC_Rasmus (talk | contribs) /* The name coincidence: how much should the article say? */ reply
  8. (diff | hist) m 09:56 Dulaglutide 3,990 +123 BiliaryBea (talk | contribs) add the structural figure and caption it properly [rollback]
  9. (diff | hist) 09:38 Analytical method validation 4,021 ±0 ResolutionRoo (talk | contribs) add the repeatability figure with the number of injections [rollback]
  10. (diff | hist) m 07:51 Custom peptide synthesis 3,249 +35 FmocFrancis (talk | contribs) state the residual-moisture target with the method it is measured by [rollback]
  11. (diff | hist) 06:20 Contract development and manufacturing organisation 2,875 ±0 PrepHPLC_Pia (talk | contribs) state the residual-moisture target with the method it is measured by [rollback]
  12. (diff | hist) 01:01 Limit of detection 3,971 +293 AAA_Analyst (talk | contribs) expand §How it is determined [rollback]
  13. (diff | hist) m 00:36 VendorInvestigate 3,585 +102 MicrodoseMagnus (talk | contribs) add category for certificates of analysis [rollback]

24 January 2025

  1. (diff | hist) m b 23:51 Amino acid analysis 2,621 ±0 ArchiveBot (talk | contribs) bot: repair redlinked category [rollback]
  2. (diff | hist) 22:32 Shanghai Wibson Biotechnology 2,196 +441 Chromatokid (talk | contribs) add the research-use-only statement to the lead rather than only the footer [rollback]
  3. (diff | hist) m 22:19 Glossary of peptide terminology 3,581 ±0 GlossaryGleb (talk | contribs) add the year of first description to each glossary term where known [rollback]
  4. (diff | hist) 21:19 Glucagon-like peptide-1 10,017 ±0 BetaCellBoyd (talk | contribs) clarify that the incretin effect is defined by the oral–intravenous comparison [rollback]
  5. (diff | hist) m 18:24 Cold chain 17,977 +307 SemaglutideSasha (talk | contribs) fix a dangling clause [rollback]
  6. (diff | hist) m b 14:19 LEADER trial 3,277 +99 StubSorterBot (talk | contribs) bot: sort category members [rollback]
  7. (diff | hist) 13:36 Repackaging 3,597 +39 CouplingCillian (talk | contribs) state the difference between a validated shipper and an insulated box [rollback]
  8. (diff | hist) m b 13:31 HOMA-IR 3,208 +30 CiteBot (talk | contribs) bot: sort category members [rollback]
  9. (diff | hist) 12:28 Chinese Peptide Company 9,146 +412 Compounding_Cate (talk | contribs) correct the regional-warehouse list — six sites, not five [rollback]
  10. (diff | hist) 11:46 Peptide harm reduction 2,785 ±0 Compounding_Cate (talk | contribs) state that the pricing data is self-reported where it is [rollback]
  11. (diff | hist) 05:21 Preparative HPLC purification 3,866 +23 CounterfeitCato (talk | contribs) rm the vendor-specific packaging detail; not general enough for the article [rollback]

23 January 2025

  1. (diff | hist) 20:31 Lixisenatide 2,936 +634 StyleSheetSybil (talk | contribs) rm duplicated pharmacokinetics — the same figures appear in the infobox [rollback]